Mirum Pharmaceuticals, Inc. (MIRM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Mirum Pharmaceuticals' CEO Christopher Peetz, speaking at the Morgan Stanley Global Healthcare Conference, reported robust commercial performance with three approved rare disease medicines, projecting $490-510 million in revenue this year. Peetz also highlighted an active pipeline, including the recently completed enrollment for the VISTAS Phase IIb study of Volixibat in PSC, with top-line data anticipated in Q2 next year. This study is the first of three potential pivotal trials expected over the next 18 months, underscoring Mirum's near-term clinical catalysts and growth trajectory.

Analysis

Mirum Pharmaceuticals is showcasing a strong dual profile of robust commercial execution and a catalyst-rich near-term pipeline. The company has guided for significant revenue of $490 million to $510 million for the current year, anchored by its portfolio of three approved rare disease medicines, which establishes a solid commercial foundation. Critically, management has highlighted a series of upcoming clinical milestones, led by the recently completed enrollment of the VISTAS Phase IIb study for Volixibat in PSC. This trial is positioned as the first of three potentially pivotal studies with readouts expected over the next 18 months. The top-line data from the VISTAS study, anticipated in Q2 of next year, represents the most immediate and significant potential value inflection point for the company.

Key Decisions for Investors

• Investors should view the $490-510 million revenue guidance as a key performance indicator for the existing commercial business, which provides a fundamental valuation floor supporting the pipeline's development costs.
• The primary forward-looking catalyst is the top-line data from the VISTAS Phase IIb study expected in Q2 of next year; the outcome of this trial will be a major driver for the stock and will influence sentiment around the two subsequent pivotal studies.
• Given the concentration of three potential pivotal readouts within the next 18 months, investors may consider the period leading up to the VISTAS data an opportunity to evaluate their position size, as positive results could significantly de-risk the pipeline and trigger a re-rating.